Difference between revisions of "Team:Aix-Marseille/HP/Interviews"

(Mireille ANSALDI)
Line 4: Line 4:
 
==Mireille ANSALDI==
 
==Mireille ANSALDI==
  
As the project grows, we had more and more questions about our bacteriophage approach. Indeed, we wanted in the first place to use ''Xylella fastidiosa''’s natural phages, but we met some difficulties. We went to see Ms. ANSALDI, who directs the “phage cycle and bacteria metabolism” unity research in LCB, CNRS Marseille, France. As an expert in the field, she is an obvious choice to seek advice on the matter. She generously granted us time for an interview.
+
As the project grows, we had more and more questions about our bacteriophage approach. Indeed, we wanted in the first place to use ''Xylella fastidiosa''’s natural phages, but we met some difficulties. We went to see Ms ANSALDI, who directs the “phage cycle and bacteria metabolism” unity research in LCB, CNRS Marseille, France. As an expert in the field, she is an obvious choice to seek advice on the matter. She generously granted us time for an interview.
  
  
Thanks to her answers, we learned that ''Xylella fastidiosa'' certainly has some resistance mechanism, such as  CRISPR and restriction enzymes. We had doubts about it, now we are fixed. She also told us that we could work on ''Xanthomonas ?'' instead of ''Xylella fastidiosa'', since the binding proteins are similar. Indeed, the work on ''Xylella fastidiosa'' is not allowed in P1 or P2 labs, whereas Xanthomonas is allowed in P2 security labs. So we will use ''Xanthomonas ?'' instead, for more safety.
+
Thanks to her answers, we learned that ''Xylella fastidiosa'' certainly has some resistance mechanism, such as  CRISPR and restriction enzymes. We had doubts about it, now we are fixed. She also told us that we could work on ''Xanthomonas campestris'' instead of ''Xylella fastidiosa'' since the binding proteins are similar. Indeed, the work on ''Xylella fastidiosa'' is not allowed in P1 or P2 labs, whereas Xanthomonas is allowed in P2 security labs. So we will use ''X.campestris'' instead, for more safety.
 
   
 
   
A TRADUIRE
 
  
''Durant l’interview, elle nous a d’ailleurs conseillé de regarder l’utilisation des prophages. Mais le manque d’informations sur des pro-phages infectant XF, et la toxicité induite par ces phages nous a aussi fait abandonné cette piste. C’est ainsi que nous sommes allés nous renseigner au sujet des phages filamenteux, et les Phage-like particles, notre projet final.''
+
Finally, she also advises us to look about the prophages. By missing information about specific prophages of ''X.fastidiosa'' and the inducible toxicity by these phages, we let this approach aside. That’s why we end up with the [[Team:Aix-Marseille/Bacteriophages|phage-like particles approach]], our final project.
 +
 
 +
To sum up, we question our phages approach with an expert opinion. Thanks to her, we change our mind about what we wanted to do. Now we are able to combine the phage’s specificity with the toxine’s efficiency.
  
''Grâce à cette interview nous avons donc remis en question notre première approche sur les phages, et grâce à cela nous avons pu combiner la spécificité des phages avec l’efficacité des toxines en nous tournant vers l’utilisation de Phage-like particle.''
 
  
 
==Jacques VAN HELDEN==
 
==Jacques VAN HELDEN==
  
 
==Marie-Agnès JACQUES==
 
==Marie-Agnès JACQUES==

Revision as of 12:14, 20 October 2017

Experts' Interviews


Mireille ANSALDI

As the project grows, we had more and more questions about our bacteriophage approach. Indeed, we wanted in the first place to use Xylella fastidiosa’s natural phages, but we met some difficulties. We went to see Ms ANSALDI, who directs the “phage cycle and bacteria metabolism” unity research in LCB, CNRS Marseille, France. As an expert in the field, she is an obvious choice to seek advice on the matter. She generously granted us time for an interview.


Thanks to her answers, we learned that Xylella fastidiosa certainly has some resistance mechanism, such as CRISPR and restriction enzymes. We had doubts about it, now we are fixed. She also told us that we could work on Xanthomonas campestris instead of Xylella fastidiosa since the binding proteins are similar. Indeed, the work on Xylella fastidiosa is not allowed in P1 or P2 labs, whereas Xanthomonas is allowed in P2 security labs. So we will use X.campestris instead, for more safety.


Finally, she also advises us to look about the prophages. By missing information about specific prophages of X.fastidiosa and the inducible toxicity by these phages, we let this approach aside. That’s why we end up with the phage-like particles approach, our final project.

To sum up, we question our phages approach with an expert opinion. Thanks to her, we change our mind about what we wanted to do. Now we are able to combine the phage’s specificity with the toxine’s efficiency.


Jacques VAN HELDEN

Marie-Agnès JACQUES